SCHEMBL2186256

SCHEMBL2186256

N#Cc1ccc(-c2c[c]cc(Cl)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 1/20 0.47
KIF11 P52732 3/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
CA12 O43570 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
CA1 P00915 1/20 0.40
MAP4K4 O95819 1/20 0.39
CYP11B2 P19099 1/20 0.39
RHEB Q15382 1/20 0.38
MAPKAPK2 P49137 1/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
NLRP3 Q96P20 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP2A6 P11509 1/20 0.37
CA3 P07451 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16918828 0.81 MMP3 (0.52) MMP3KIF11MAOAMAOBCA12
SCHEMBL28916864 0.81 AHR (0.46) KIF11MAOBLMNAMAPTTSHR
SCHEMBL2184323 0.79 CLK4 (0.47) MAOBMAP4K4GABRA1GABRG2GABRB3
SCHEMBL2184380 0.78 KIF11 (0.50) MMP3KIF11CA12CA2CA9
SCHEMBL4446050 0.78 MAOA (0.64) MMP3KIF11MAOAMAOBCA12
SCHEMBL21302775 0.78 GRM5 (0.51) MMP3KIF11MAOAMAOBCA12
SCHEMBL21808750 0.77 CYP1A2 (0.54) MMP3MAOBMAP4K4LMNATSHR
SCHEMBL16908393 0.76 TAAR1 (0.53) MMP3KIF11MAOBCYP11B2MAPT
SCHEMBL27938965 0.75 ALDH1A1 (0.41) CA12CA2CA9MAPTALDH1A1
SCHEMBL396846 0.75 MMP3 (0.74) MMP3KIF11MAOAMAOBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166132-A1 Gamma Secretase Modulators AMGEN INC. (US) 2011-07-07 US claimed
EP-2231602-A1 GAMMA SECRETASE MODULATORS Amgen, Inc (US) 2010-09-29 EP claimed
WO-2009075874-A1 GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-06-18 WO claimed
US-20110166132-A1 Gamma Secretase Modulators AMGEN INC. (US) 2011-07-07 US disclosed
EP-2231602-A1 GAMMA SECRETASE MODULATORS Amgen, Inc (US) 2010-09-29 EP disclosed
WO-2009075874-A1 GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166132-A1 Gamma Secretase Modulators BACE1, BACE2, PSEN1 MMP3 1134/4885KIF11 4426/4885MAOA 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.